Difluprednate Property

Melting point:

191-194°

alpha 

D22 +31.7° (c = 0.5 in dioxane)

Boiling point:

600.3±55.0 °C(Predicted)

Density 

1.1869 (estimate)

storage temp. 

2-8°C

solubility 

Dioxane (Slightly), Methanol (Slightly)

form 

Solid

pka

12.56±0.70(Predicted)

color 

White

Safety

WGK Germany 

2

RTECS 

TU3831500

HS Code 

2937.29.9095

Toxicity

mouse,LD50,intraperitoneal,146mg/kg (146mg/kg),BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)BEHAVIORAL: FOOD INTAKE (ANIMAL),Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 15, Pg. 1066, 1984.

Hazard and Precautionary Statements (GHS)

Symbol(GHS)

Signal word

Warning

Hazard statements

H361Suspected of damaging fertility or the unborn child

Precautionary statements

P201Obtain special instructions before use.

P202Do not handle until all safety precautions have been read and understood.

P280Wear protective gloves/protective clothing/eye protection/face protection.

P308+P313IF exposed or concerned: Get medical advice/attention.

P405Store locked up.

P501Dispose of contents/container to..…

Difluprednate Chemical Properties,Usage,Production

Description

Difluprednate is a synthetic glucocorticoid that potently activates the glucocorticoid receptor (K_i = 78 pM). In vivo, ocular administration of difluprednate (0.05% w/v) increases intraocular pressure in sheep. Formulations containing difluprednate have been used to treat diabetic macular edema and inflammation following cataract surgery.

Chemical Properties

White Solid

Originator

Epitopic,Clin Midy,France,1978

Uses

Difluprednate-d3 is the isotope labeled form of Difluprednate (D445925), a corticosteroid (derivative of prednisolone), approved for the treatment of post-operative ocular inflammation.

Definition

ChEBI: Difluprednate is a corticosteroid hormone and a butyrate ester.

Manufacturing Process

Orthoesterification: A mixture of 1 g of 6α,9α-difluoroprednisolone, 10 mg of p-toluenesulfonic acid, 5 cc of dimethylformamide and 3 cc of methyl orthobutyrate is heated for 15 hours on an oil bath at 105°C while a slow stream of nitrogen is passed through the mixture so that the methanol produced as a by-product of the reaction, is distilled off. After addition of several drops of pyridine to neutralize the acid catalyst, the reaction mixture is evaporated under vacuum and there is obtained a solid residue which is taken up with methanol, and filtered. The product is recrystallized from a methylene chloride-methanol mixture to yield 682 mg of 6α,9αdifluoroprednisolone 17α,21-methylorthobutyrate, also identified as 17α,21- (1'-methoxy)-n-butylidenedioxy-6α,9α-difluoro-δ1,4-pregnadiene-11β-ol-3,20- dione, MP 194°C-198°C.
Upon chromatography of the mother liquor on a column of alumina another 338 mg of a crystalline mixture of the epimeric orthobutyrates are isolated.
Hydrolysis: A suspension of 1 g of the 6α,9α-difluoroprednisolone 17α,21- methylorthobutyrate in 10 cc of methanol is treated with 2 cc of a 2 N aqueous solution of oxalic acid and heated on a water bath at 40°-50°C for about 5-10 minutes and, afterwards, the mixture is concentrated under vacuum. The residue is then shaken with water, the insoluble product is filtered off and then dried. The solid material is recrystallized from acetoneether and 6α,9α-difluoroprednisolone 17-butyrate is obtained, MP 193°-196°C
Esterification: A solution of 500 mg of 6α,9α-difluoroprednisolone-17-butyrate in 2.5 cc of pyridine is treated with 1.25 cc of acetic anhydride and the reaction mixture permitted to stand overnight at 0°C. The reaction mixture is then poured into ice water and the crystalline precipitate formed is filtered off and recrystallized from a methylene chloride-ether-petroleum ether mixture to yield 494 mg of 6α,9α-difluoroprednisolone 17-butyrate, 21-acetate; MP 191°- 194°C.

Therapeutic Function

Antiinflammatory

General Description

Difluprednate, 21-(acetyloxy)-6α,9-difluoro-11β-hydroxy-17-(1-oxobutoxy)pregna-1,4-diene-3,20-dione is being developed (phase III) as a topical ophthalmicemulsion to treat inflammatory eye diseases.